Ana Flávia Minutti , João Pedro Sasse , Ana Clécia dos Santos Silva , Thais Agostinho Martins , Valentina Martinez , Beatriz de Souza Lima Nino , Fernando de Souza Rodrigues , Luiz Daniel de Barros , João Luis Garcia
{"title":"Evaluation of a DNA vector plasmid encoding a partial rop18 gene from toxoplasma gondii in domestic cats as a vaccine candidate","authors":"Ana Flávia Minutti , João Pedro Sasse , Ana Clécia dos Santos Silva , Thais Agostinho Martins , Valentina Martinez , Beatriz de Souza Lima Nino , Fernando de Souza Rodrigues , Luiz Daniel de Barros , João Luis Garcia","doi":"10.1016/j.vaccine.2025.126965","DOIUrl":null,"url":null,"abstract":"<div><div>The present study aimed to evaluate a DNA vector plasmid encoding a partial <em>rop18</em> gene from <em>Toxoplasma gondii</em> in domestic cats as a potential vaccine candidate. Four domestic cats (<em>Felis catus</em>) were used, of which two animals received 25 μg of pcDNA 3.1 + <em>rop18</em>, and two received 25 μg of pcDNA 3.1. All animals received intramuscular immunizations with four doses every three weeks along with 1.5 % levamisole. Thirty days after the last immunization, the animals were infected with 300 tissue cysts from ToxoDB #182 strain, a non-archetypal genotype isolated from a wild cat. Fecal examinations were performed for oocyst shedding. Enzyme-linked immunosorbent assay and western blotting analyses with recombinant ROP18 were performed to assess the humoral immune response. Animals that received plasmid containing the partial <em>T. gondii rop18</em> gene produced specific IgG antibodies and shed 53.3 % fewer oocysts than controls. The two groups of animals showed no statistically significant differences (<em>p</em> > 0.05) in oocyst shedding; however, they showed significant differences in the detection of anti-<em>Toxoplasma</em> antibodies (<em>p</em> < 0.05). In conclusion, the <em>T. gondii rop18</em> gene is a potential vaccine candidate against oocyst shedding in cats.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"54 ","pages":"Article 126965"},"PeriodicalIF":4.5000,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X25002622","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The present study aimed to evaluate a DNA vector plasmid encoding a partial rop18 gene from Toxoplasma gondii in domestic cats as a potential vaccine candidate. Four domestic cats (Felis catus) were used, of which two animals received 25 μg of pcDNA 3.1 + rop18, and two received 25 μg of pcDNA 3.1. All animals received intramuscular immunizations with four doses every three weeks along with 1.5 % levamisole. Thirty days after the last immunization, the animals were infected with 300 tissue cysts from ToxoDB #182 strain, a non-archetypal genotype isolated from a wild cat. Fecal examinations were performed for oocyst shedding. Enzyme-linked immunosorbent assay and western blotting analyses with recombinant ROP18 were performed to assess the humoral immune response. Animals that received plasmid containing the partial T. gondii rop18 gene produced specific IgG antibodies and shed 53.3 % fewer oocysts than controls. The two groups of animals showed no statistically significant differences (p > 0.05) in oocyst shedding; however, they showed significant differences in the detection of anti-Toxoplasma antibodies (p < 0.05). In conclusion, the T. gondii rop18 gene is a potential vaccine candidate against oocyst shedding in cats.
期刊介绍:
Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.